I n a recent SEC filing, MiNK Therapeutics, Inc., a biopharmaceutical company, declared the implementation of a reverse stock split of its common stock. The decision was made official following a ...

Mink Therapeutics, a biotechnology firm focused on innovative therapies, has reached a 52-week high, with its stock price climbing to $8.84. The stock has shown impressive momentum with a 26.83% ...